Antegenes
Digital health company implementing advanced genetic tests for personalized prevention of cancer and other complex diseases.
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 179 % | 15 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Antegenes operates in the healthcare sector, specializing in genetic testing for cancer risk assessment. The company leverages advanced polygenic risk score technology to analyze thousands of genetic variants and personal background information, providing personalized and unique results. Antegenes offers tests for various types of cancer, including breast, prostate, colorectal, and melanoma. Clients can either upload existing DNA data from services like 23andMe, MyHeritage, Genes For Good, Ancestry DNA, and Family Tree DNA, or opt for a new DNA sample collection. The service is designed to be convenient, allowing clients to perform tests from the comfort of their homes. Antegenes generates revenue through the sale of these genetic tests and associated medical reports, which include advice for cancer prevention and early detection. The company is certified under ISO 13485:2016, ensuring high-quality standards in its operations.
Keywords: genetic testing, cancer prevention, polygenic risk score, personalized medicine, DNA data, healthcare, breast cancer, prostate cancer, colorectal cancer, melanoma.